IMATILATE 400 TABLET

Product Description

IMATILATE 400 TABLET contains Imatinib Mesylate 400mg, a targeted tyrosine kinase inhibitor (TKI) widely used in the treatment of various cancers, including Chronic Myeloid Leukemia (CML) and Gastrointestinal Stromal Tumors (GISTs). This high-potency oncology formulation delivers effective, targeted cancer therapy by inhibiting abnormal cancer cell growth at the molecular level.

Manufactured under WHO-GMP certified facilities, IMATILATE 400 ensures consistent therapeutic efficacy, patient safety, and global quality standards, making it a preferred choice for oncology centers, hospital pharmacies, and bulk procurement channels.

Key Benefits:

• Contains Imatinib 400mg a proven molecule in targeted cancer therapy

• Effective in treating CML, Ph+ ALL, and GIST

• Oral administration for ease of patient compliance

• High stability, long shelf life, and trusted therapeutic results

Applications:

• First-line treatment for Philadelphia chromosome-positive CML

• Indicated for relapsed or refractory Ph+ Acute Lymphoblastic Leukemia

• Also used in dermatofibrosarcoma protuberans and certain hypereosinophilic syndromes

Why Choose IMATILATE 400 TABLET?

• Oncology-grade formulation with global therapeutic relevance

• Competitive pricing for bulk buyers, tenders, and institutional supply

• Available for export, wholesale distribution, and contract manufacturing